Bristol Myers Squibb discloses results from it's Phase I Breakfree-2 trial of CAR-T therapy zola-cel for multiple sclerosis.
|Articles|June 1, 2009
Elan in talks to sell stake to Bristol
1 June 2009
Advertisement
Irish biotech firm is reportedly discussing selling a minority-stake to Bristol-Myers Squibb.
According to a report in
In January, Elan hired Citigroup to conduct a strategic review of its business, which it said could lead to a sale or merger of the company.
Elan and Bristol-Myers Squibb declined to comment.
www.elan.com
www.bms.com
Advertisement
Related to this article
Pharmaceutical and health economist Dr. Nadine Zawadzki, Senior Director, FTI Consulting joins the Ron Lanton Report to discuss how value is defined and measured across healthcare.
The Treasury Department is proposing rules to add biotechnology to its Outbound Investment Security Program under the COINS Act.
Lilly’s Foundayo receives a positive CHMP opinion for obesity and type 2 diabetes — putting the oral GLP-1 pill on course for EU approval.
Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.
Shionogi’s Dr. Draica on why preventative antivirals matter — and how its HIV and flu prevention heritage shaped XOCOVA’s post-exposure focus.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: Teva Acquires BXCL501 for $57.5 Million Upfront, Rumi Therapeutics Enters Option Agreement for Fragile X PDE2 Inhibitor From Enthorin
2
The Next Biopharma Revolution: Quantum Computing
3
How Medications like XOCOVA Prevent Illness After Exposure to COVID-19
4
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
5